Form Tyoe: 20-F-A

Analyst Summary

• Cellectis S.A. filed an amendment (Form 20-F/A) to correct administrative errors in auditor consents (Exhibits 15.1 and 15.2).
• The original errors included an omitted conformed signature from KPMG SA and an incorrect date in the consent from Ernst & Young et Autres.
• The amendment includes corrected exhibits and new certifications from the CEO and CFO.
• The correction of these errors demonstrates Cellectis’ commitment to accurate and compliant reporting.
• A comprehensive analysis of Cellectis’ financial performance requires a review of the original Form 20-F filed on March 14, 2025, focusing on financial statements, MD&A, and risk factors.
• Key agreements with AstraZeneca and Servier are relevant for understanding strategic collaborations.